Boston Trust Walden’s Vertex Pharmaceuticals VRTX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | $217K | Hold |
485
| – | – | ﹤0.01% | 384 |
|
|
2025
Q4 | $220K | Buy |
+485
| New | +$209K | ﹤0.01% | 375 |
|
|
2025
Q3 | – | Sell |
-485
| Closed | -$216K | – | 403 |
|
|
2025
Q2 | $216K | Sell |
485
-125
| -20% | -$57.6K | ﹤0.01% | 368 |
|
|
2025
Q1 | $296K | Sell |
610
-200
| -25% | -$93.2K | ﹤0.01% | 348 |
|
|
2024
Q4 | $326K | Sell |
810
-150
| -16% | -$69.5K | ﹤0.01% | 342 |
|
|
2024
Q3 | $446K | Sell |
960
-150
| -14% | -$72.1K | ﹤0.01% | 324 |
|
|
2024
Q2 | $520K | Hold |
1,110
| – | – | ﹤0.01% | 316 |
|
|
2024
Q1 | $464K | Hold |
1,110
| – | – | ﹤0.01% | 323 |
|
|
2023
Q4 | $452K | Hold |
1,110
| – | – | ﹤0.01% | 318 |
|
|
2023
Q3 | $386K | Hold |
1,110
| – | – | ﹤0.01% | 318 |
|
|
2023
Q2 | $391K | Hold |
1,110
| – | – | ﹤0.01% | 320 |
|
|
2023
Q1 | $350K | Hold |
1,110
| – | – | ﹤0.01% | 328 |
|
|
2022
Q4 | $321K | Hold |
1,110
| – | – | ﹤0.01% | 335 |
|
|
2022
Q3 | $321K | Hold |
1,110
| – | – | ﹤0.01% | 325 |
|
|
2022
Q2 | $313K | Sell |
1,110
-90
| -8% | -$24.1K | ﹤0.01% | 331 |
|
|
2022
Q1 | $313K | Hold |
1,200
| – | – | ﹤0.01% | 344 |
|
|
2021
Q4 | $264K | Sell |
1,200
-33
| -3% | -$6.42K | ﹤0.01% | 368 |
|
|
2021
Q3 | $224K | Buy |
1,233
+33
| +3% | +$6.44K | ﹤0.01% | 376 |
|
|
2021
Q2 | $242K | Hold |
1,200
| – | – | ﹤0.01% | 369 |
|
|
2021
Q1 | $258K | Hold |
1,200
| – | – | ﹤0.01% | 352 |
|
|
2020
Q4 | $284K | Sell |
1,200
-308
| -20% | -$70.7K | ﹤0.01% | 348 |
|
|
2020
Q3 | $410K | Hold |
1,508
| – | – | 0.01% | 322 |
|
|
2020
Q2 | $438K | Hold |
1,508
| – | – | 0.01% | 318 |
|
|
2020
Q1 | $359K | Hold |
1,508
| – | – | 0.01% | 320 |
|
|
2019
Q4 | $330K | Hold |
1,508
| – | – | ﹤0.01% | 349 |
|
|
2019
Q3 | $255K | Hold |
1,508
| – | – | ﹤0.01% | 359 |
|
|
2019
Q2 | $277K | Hold |
1,508
| – | – | ﹤0.01% | 356 |
|
|
2019
Q1 | $277K | Hold |
1,508
| – | – | ﹤0.01% | 359 |
|
|
2018
Q4 | $250K | Hold |
1,508
| – | – | ﹤0.01% | 358 |
|
|
2018
Q3 | $291K | Sell |
1,508
-50
| -3% | -$8.9K | ﹤0.01% | 357 |
|
|
2018
Q2 | $265K | Hold |
1,558
| – | – | ﹤0.01% | 363 |
|
|
2018
Q1 | $254K | Sell |
1,558
-625
| -29% | -$102K | ﹤0.01% | 368 |
|
|
2017
Q4 | $327K | Hold |
2,183
| – | – | ﹤0.01% | 353 |
|
|
2017
Q3 | $332K | Sell |
2,183
-125
| -5% | -$18.8K | 0.01% | 352 |
|
|
2017
Q2 | $297K | Buy |
+2,308
| New | +$278K | ﹤0.01% | 355 |
|
Other funds holding VRTX
VCM
VPM
Boston Trust Walden's VRTX Position: Q1 2026 in Review
Boston Trust Walden held its Vertex Pharmaceuticals (VRTX) position steady in Q1 2026 at 485 shares worth $217K. The position accounts for ﹤0.01% of the portfolio, ranked #384.
Boston Trust Walden first reported a position in VRTX in Q2 2017 and has held it in 35 quarters since. The position peaked at $520K in Q2 2024. 1,687 funds tracked by Wall St. Rank hold VRTX as of Q1 2026.
- Boston Trust Walden held 485 shares of Vertex Pharmaceuticals worth $217K as of Q1 2026.
- Boston Trust Walden left its Vertex Pharmaceuticals share count unchanged in Q1 2026.
- Vertex Pharmaceuticals made up ﹤0.01% of Boston Trust Walden's portfolio in Q1 2026, its #384 holding.
- Boston Trust Walden first reported a position in Vertex Pharmaceuticals in Q2 2017 and has held it in 35 quarters since.
- Boston Trust Walden's Vertex Pharmaceuticals position peaked at $520K in Q2 2024.
- 1,687 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q1 2026.
Based on Boston Trust Walden's 13F filing for Q1 2026, filed 24 Apr 2026.